in the screening group and 95 (2,322 cancers) in the control group (rate ratio, 1.22; 95 % confidence interval [CI]: 1.16 to 1.29). The incidence of death per 10,000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1...
The National Institute for Health and Clinical Excellence’s guideline on “Chronic fatigue syndrome/myalgicencephalomyelitis (or encephalopathy): Diagnosis and management of CFS/ME in adults and children” (NICE, 2007) stated that the following drugs should not be used for the treatment of CFS/ME...
Here is the link to the INTERACT Training for Emergency Services: http://www.healthcarefornewengland.org/providers/nursing-home/#tool Then select “INTERACT Training for Emergency Services” The training is about 12 minutes in length and covers the new acute care transfer process between a partic...
Enderby P, Petheram B. Changes in referral to speech and language therapy. Int J Lang Commun Disord. 1998;33 Suppl:16-20. Enderby PM, John A. Therapy outcome measures in speech and language therapy: comparing performance between different providers. Int J Lang Commun Disord. 1999;34(4):4...
VELscope is intended to be used by dentists or health-care providers as an adjunct to traditional oral examination by incandescent light to enhance the visualization of oral mucosal abnormalities that may not be apparent or visible to the naked eye, such as oral cancer or pre-malignant dysplasia...
Precertification of alpha 1-proteinase inhibitors (Aralast NP, Glassia, Prolastin-C, and Zemaira) is required of all Aetna participating providers and members in applicable plan designs. For precertification of alpha 1-proteinase inhibitors, call (866) 752-7021 or fax (888) 267-3277. For Stat...
Precertification of immune globulin human intramuscular injection (IGIM) (GamaSTAN) is required of all Aetna participating providers and members in applicable plan designs. For precertification of immune globulin human intramuscular injection (IGIM) (GamaSTAN), call (866) 752-7021 (commercial) or ...
Assuming a very-low uptake, these investigators estimated that the budget impact of publicly funding PLA in Ontario over the next 5 years is about $3.44 million if the test is used exclusively by primary care providers, or about $2.56 million if it is used exclusively by specialists. The ...
The lack of a significant survival benefit with FETO in fetuses with moderate pulmonary hypoplasia should prompt providers to encourage participation in additional randomized trials of FETO efficacy and outcomes and to avoid offering FETO outside such trials. The editorialist concluded that the current...
U.S. Food and Drug Administration (FDA). Risks Associated with Use of Rupture of Membranes Tests - Letter to Health Care Providers. Silver Spring, MD: FDA; August 9, 2018. van der Ham DP, van Melick MJ, Smits L, et al. Methods for the diagnosis of rupture of the fetal membranes ...